Filter Your Results




Tofersen for Treatment of Familial Amyotrophic Lateral Sclerosis

Wednesday, May 01, 2019—An early-stage trial for tofersen (BIIB067; Biogen, Cambridge, MA) an investigational drug for amyotrophic lateral sclerosis (ALS), showed that the drug is linked to slower pr…

Nusinersen Efficacy for Later-Onset Spinal Muscular Atrophy Types II and III

Wednesday, April 24, 2019—April 24, 2019 -- Children with later-onset spinal muscular atrophy (SMA) types II and III treated with nusinersen (Spinraza; Biogen, Cambridge MA) had motor function improvem…

Biomarker Study Aims to Advance Understanding of ALS Diagnosis and Treatment

Monday, April 01, 2019—A clinical study starting in late 2019 will identify and measure biomarkers in patients with amyotrophic lateral sclerosis (ALS) and evaluate the treatment effect of edaravone…

Patient Advocacy Organizations Join Forces to Improve Care for Spinal Muscular Atrophy

Thursday, March 21, 2019—Patient advocacy organizations are partnering to obtain real-world evidence to advance research, drug development, and access to therapies for children and adults with spinal …

First Cohort Fully Treated in Phase 1/2a Study of Cell Transplants for Treatment of Amyotrophic Lateral Sclerosis

Monday, March 11, 2019—In a phase 1/2a study, 5 patients with amyotrophic lateral scleroris (ALS) have had healthy astrocytes derived from stem cells (AstroRx; Kadimastem, Ness Ziona, Israel) transp…

Patient Impact Award for Liquid Riluzole Treatment for ALS

Friday, March 01, 2019—The Patient Impact Award from Life Sciences Pennsylvania pharmaceutical company will be recognized in March for the US launch of the first easy-to-swallow, thickened riluzole …

National Online Directory of Amyotrophic Lateral Sclerosis Specialists Launched

Monday, February 04, 2019—A national online database of healthcare providers (HCPs) who treat amyotrophic lateral sclerosis (ALS) has been launched by Mitsubishi Tanabe Pharma America (MTPA). The …

Neuromuscular Community Survey Identifies Key Issues

Thursday, January 17, 2019—The Muscular Dystrophy Association (MDA) has announced results of a landmark survey that asked more than 3,000 people affected by neuromuscular disease (NMD) about their key a…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.